SCHEMBL2244641

SCHEMBL2244641

CC(C)(Cc1ccccc1)N(C(=O)c1ccc(-c2cccc(F)c2)cc1)[C@@H](CCC(N)=O)C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 2/20 0.38
TRPM8 Q7Z2W7 2/20 0.38
MMP8 P22894 1/20 0.38
MMP12 P39900 1/20 0.38
ADAMTS5 Q9UNA0 1/20 0.38
PPARG P37231 1/20 0.37
DRD2 P14416 1/20 0.37
DRD4 P21917 1/20 0.37
ICMT O60725 2/20 0.37
MMP3 P08254 1/20 0.37
GRIN2B Q13224 2/20 0.37
FFAR1 O14842 1/20 0.37
HSD17B2 P37059 2/20 0.36
HSD17B1 P14061 1/20 0.36
GPR88 Q9GZN0 1/20 0.36
GPR34 Q9UPC5 1/20 0.35
MME P08473 1/20 0.35
ACE P12821 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2245193 0.91 MMP2 (0.43) MMP2TRPM8MMP8MMP12ADAMTS5
SCHEMBL2245867 0.91 MMP2 (0.40) MMP2MMP8MMP12ADAMTS5HSD17B2
SCHEMBL2252602 0.90 TP53 (0.35) MMP2TRPM8MMP8MMP12ADAMTS5
SCHEMBL2248091 0.88 HSD17B2 (0.41) MMP2TRPM8MMP8MMP12ADAMTS5
SCHEMBL2245312 0.88 HSD17B1 (0.43) MMP2TRPM8MMP8MMP12ADAMTS5
SCHEMBL2244933 0.87 HSD17B2 (0.51) GRIN2BFFAR1HSD17B2GPR88MME
SCHEMBL2244705 0.87 RXRA (0.42) MMP2TRPM8MMP8MMP12ADAMTS5
SCHEMBL2244927 0.86 PPARG (0.37) MMP2PPARGALDH1A1HPGDLIMK2
SCHEMBL2245162 0.86 ERN1 (0.36) MMP2MMP8MMP12ADAMTS5HSD17B2
SCHEMBL2247786 0.86 HSD17B2 (0.46) MMP2MMP8MMP12ADAMTS5FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043066-A1 Glutamate aggrecanase inhibitors WYETH (US) 2007-02-22 US claimed
US-7998965-B2 Glutamate aggrecanase inhibitors WYETH LLC (US) 2011-08-16 US disclosed
US-20100010012-A1 GLUTAMATE AGGRECANASE INHIBITORS WYETH (US) 2010-01-14 US disclosed
US-7553873-B2 Glutamate aggrecanase inhibitors WYETH (US) 2009-06-30 US disclosed
EP-1902014-A2 GLUTAMATE AGGRECANASE INHIBITORS Wyeth (US) 2008-03-26 EP disclosed
US-20070043066-A1 Glutamate aggrecanase inhibitors WYETH (US) 2007-02-22 US disclosed
WO-2007008994-A2 GLUTAMATE AGGRECANASE INHIBITORS WYETH (US) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010012-A1 GLUTAMATE AGGRECANASE INHIBITORS ADAMTS5, ADAMTS1, ADAMTS7 MMP2 49/4885TRPM8 1187/4885MMP8 70/4885
US-20070043066-A1 Glutamate aggrecanase inhibitors ADAMTS5, ADAMTS1, ADAMTS7 MMP2 49/4885TRPM8 1187/4885MMP8 70/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.